《新股消息》據報Aquila Acquisition本周配售 料成本港首隻SPAC
市場消息指,Aquila Acquisition最快將在本周中期展開路演及進行配售,預期集資約2億至3億美元,惟市場關注目前市況波動,未知會否影響其上市時間表。
Aquila Acquisition發起人為招銀國際資產管理及公司管理層持股的AAC Mgmt Holding Ltd,主要專注於投資亞洲新經濟行業內有科技賦能的公司,例如綠色能源、生命科學及先進科技與製造行業,由摩根士丹利及招銀國際擔任聯席保薦人,為本港首家申請上市的特殊目的收購公司(SPAC),於今年1月17日遞交上市申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.